Search Results - "Supko, Jeffrey"

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma by Vogl, Dan T, Raje, Noopur, Jagannath, Sundar, Richardson, Paul, Hari, Parameswaran, Orlowski, Robert, Supko, Jeffrey G, Tamang, David, Yang, Min, Jones, Simon S, Wheeler, Catherine, Markelewicz, Robert J, Lonial, Sagar

“…Histone deacetylase (HDAC) inhibition improves the efficacy of proteasome inhibition for multiple myeloma but adds substantial toxicity. Preclinical models…”
Get full text

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial by Yee, Andrew J, MD, Bensinger, William I, MD, Supko, Jeffrey G, PhD, Voorhees, Peter M, MD, Berdeja, Jesus G, MD, Richardson, Paul G, Prof, Libby, Edward N, MD, Wallace, Ellen E, BA, Birrer, Nicole E, BA, Burke, Jill N, MSN, Tamang, David L, PhD, Yang, Min, PhD, Jones, Simon S, PhD, Wheeler, Catherine A, MD, Markelewicz, Robert J, MD, Raje, Noopur S, Dr

“…Summary Background Histone deacetylase (HDAC) inhibitors are an important new class of therapeutics for treating multiple myeloma. Ricolinostat (ACY-1215) is…”
Get full text

Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 by VROOMAN, Lynda M, STEVENSON, Kristen E, LAVERDIERE, Caroline, LIPSHULTZ, Steven E, MICHON, Bruno, SCHORIN, Marshall, RELLING, Mary V, COHEN, Harvey J, NEUBERG, Donna S, SALLAN, Stephen E, SILVERMAN, Lewis B, SUPKO, Jeffrey G, O'BRIEN, Jane, DAHLBERG, Suzanne E, ASSELIN, Barbara L, ATHALE, Uma H, CLAVELL, Luis A, KELLY, Kara M, KUTOK, Jeffery L

“…We assessed the toxicity and efficacy of dexamethasone and a novel dosing method of Escherichia coli L-asparaginase (EC-Asnase) in children and adolescents…”
Get full text

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme by Rosenfeld, Myrna R, Ye, Xiaobu, Supko, Jeffrey G, Desideri, Serena, Grossman, Stuart A, Brem, Steven, Mikkelson, Tom, Wang, Daniel, Chang, Yunyoung C, Hu, Janice, McAfee, Quentin, Fisher, Joy, Troxel, Andrea B, Piao, Shengfu, Heitjan, Daniel F, Tan, Kay-See, Pontiggia, Laura, O'Dwyer, Peter J, Davis, Lisa E, Amaravadi, Ravi K

“…Preclinical studies indicate autophagy inhibition with hydroxychloroquine (HCQ) can augment the efficacy of DNA-damaging therapy. The primary objective of this…”
Get full text

Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic by Bird, Gregory H., Madani, Navid, Perry, Alisa F., Princiotto, Amy M., Supko, Jeffrey G., He, Xiaoying, Gavathiotis, Evripidis, Sodroski, Joseph G., Walensky, Loren D., Snyder, Solomon H.

“…The pharmacologic utility of lengthy peptides can be hindered by loss of bioactive structure and rapid proteolysis, which limits bioavailability. For example,…”
Get full text

Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model by McDannold, Nathan, Zhang, Yongzhi, Supko, Jeffrey G, Power, Chanikarn, Sun, Tao, Peng, Chengueng, Vykhodtseva, Natalia, Golby, Alexandra J, Reardon, David A

“…The blood-brain barrier (BBB) restricts delivery of most chemotherapy agents to brain tumors. Here, we investigated a clinical focused ultrasound (FUS) device…”
Get full text

Blood-brain barrier disruption and delivery of irinotecan in a rat model using a clinical transcranial MRI-guided focused ultrasound system by McDannold, Nathan, Zhang, Yongzhi, Supko, Jeffrey G., Power, Chanikarn, Sun, Tao, Vykhodtseva, Natalia, Golby, Alexandra J., Reardon, David A.

“…We investigated controlled blood-brain barrier (BBB) disruption using a low-frequency clinical transcranial MRI-guided focused ultrasound (TcMRgFUS) device and…”
Get full text

Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial by Xu, Ran, Shimizu, Fumiko, Hovinga, Koos, Beal, Kathryn, Karimi, Sasan, Droms, Leif, Peck, Kyung K, Gutin, Philip, Iorgulescu, J Bryan, Kaley, Thomas, DeAngelis, Lisa, Pentsova, Elena, Nolan, Craig, Grommes, Christian, Chan, Timothy, Bobrow, Dylan, Hormigo, Adilia, Cross, Justin R, Wu, Nian, Takebe, Naoko, Panageas, Katherine, Ivy, Percy, Supko, Jeffrey G, Tabar, Viviane, Omuro, Antonio

“…High-grade gliomas are associated with a dismal prognosis. Notch inhibition via the gamma-secretase inhibitor RO4929097 has emerged as a potential therapeutic…”
Get full text

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials by Albrecht, Brian K, Gehling, Victor S, Hewitt, Michael C, Vaswani, Rishi G, Côté, Alexandre, Leblanc, Yves, Nasveschuk, Christopher G, Bellon, Steve, Bergeron, Louise, Campbell, Robert, Cantone, Nico, Cooper, Michael R, Cummings, Richard T, Jayaram, Hariharan, Joshi, Shivangi, Mertz, Jennifer A, Neiss, Adrianne, Normant, Emmanuel, O’Meara, Michael, Pardo, Eneida, Poy, Florence, Sandy, Peter, Supko, Jeffrey, Sims, Robert J, Harmange, Jean-Christophe, Taylor, Alexander M, Audia, James E

“…In recent years, inhibition of the interaction between the bromodomain and extra-terminal domain (BET) family of chromatin adaptors and acetyl-lysine residues…”
Get full text

A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas by HONG, David S, KURZROCK, Razelle, MIER, James, KONOPLEVA, Marina, KONOPLEV, Sergej, ANDREEFF, Michael, KUFE, Donald, LAZARUS, Hillard, SHAPIRO, Geoffrey I, DEZUBE, Bruce J, SUPKO, Jeffrey G, XIAOYING HE, NAING, Aung, WHELER, Jennifer, LAWRENCE, Donald, EDER, Joseph Paul, MEYER, Colin J, FERGUSON, Deborah A

“…Bardoxolone methyl, a novel synthetic triterpenoid and antioxidant inflammation modulator, potently induces Nrf2 and inhibits NF-κB and Janus-activated…”
Get full text

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib by Wagle, Nikhil, Grabiner, Brian C, Van Allen, Eliezer M, Hodis, Eran, Jacobus, Susanna, Supko, Jeffrey G, Stewart, Michelle, Choueiri, Toni K, Gandhi, Leena, Cleary, James M, Elfiky, Aymen A, Taplin, Mary Ellen, Stack, Edward C, Signoretti, Sabina, Loda, Massimo, Shapiro, Geoffrey I, Sabatini, David M, Lander, Eric S, Gabriel, Stacey B, Kantoff, Philip W, Garraway, Levi A, Rosenberg, Jonathan E

“…Understanding the genetic mechanisms of sensitivity to targeted anticancer therapies may improve patient selection, response to therapy, and rational treatment…”
Get more information

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l -asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial by Place, Andrew E, MD, Stevenson, Kristen E, MS, Vrooman, Lynda M, MD, Harris, Marian H, MD, Hunt, Sarah K, MPH, O'Brien, Jane E, BA, Supko, Jeffrey G, PhD, Asselin, Barbara L, MD, Athale, Uma H, MD, Clavell, Luis A, Prof, Cole, Peter D, MD, Kelly, Kara M, Prof, Laverdiere, Caroline, MD, Leclerc, Jean-Marie, MD, Michon, Bruno, MD, Schorin, Marshall A, Prof, Welch, Jennifer J G, MD, Lipshultz, Steven E, Prof, Kutok, Jeffery L, MD, Blonquist, Traci M, MS, Neuberg, Donna S, ScD, Sallan, Stephen E, Prof, Silverman, Lewis B, Dr

“…Summary Background l -asparaginase is a universal component of treatment for childhood acute lymphoblastic leukaemia, and is usually administered…”
Get full text

Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target by Chen, Ting, Ozel, Duygu, Qiao, Yuan, Harbinski, Fred, Chen, Limo, Denoyelle, Séverine, He, Xiaoying, Zvereva, Nela, Supko, Jeffrey G, Chorev, Michael, Halperin, Jose A, Aktas, Bertal H

“…Overabundance of the eIF2–GTP–Met-tRNAi translational initiation complex has been linked to malignant transformation. N , N '-diarylurea chemical probes that…”
Get full text

A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer by Goldberg, Sarah B, Supko, Jeffrey G, Neal, Joel W, Muzikansky, Alona, Digumarthy, Subba, Fidias, Panos, Temel, Jennifer S, Heist, Rebecca S, Shaw, Alice T, McCarthy, Patricia O, Lynch, Thomas J, Sharma, Sreenath, Settleman, Jeffrey E, Sequist, Lecia V

“…This investigator-initiated study explores the safety, maximum tolerated dose, clinical response, and pharmacokinetics of hydroxychloroquine (HCQ) with and…”
Get more information

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001 by Vrooman, Lynda M, Blonquist, Traci M, Stevenson, Kristen E, Supko, Jeffrey G, Hunt, Sarah K, Cronholm, Sarah M, Koch, Victoria, Kay-Green, Samantha, Athale, Uma H, Clavell, Luis A, Cole, Peter D, Harris, Marian H, Kelly, Kara M, Laverdiere, Caroline, Leclerc, Jean-Marie, Michon, Bruno, Place, Andrew E, Schorin, Marshall A, Welch, Jennifer J G, Neuberg, Donna S, Sallan, Stephen E, Silverman, Lewis B

“…Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia (ALL) Consortium Protocol 11-001 assessed efficacy and toxicity of calaspargase pegol (calaspargase),…”
Get full text

Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins by Rocio Garcia-Carbonero, Jeffrey G. Supko

“…The camptothecins are a maturing class of anticancer agents. In this article, we review the pharmacology and antitumor activity of the camptothecin analogues…”
Get full text

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib by Lynch, Thomas J, Bell, Daphne W, Sordella, Raffaella, Gurubhagavatula, Sarada, Okimoto, Ross A, Brannigan, Brian W, Harris, Patricia L, Haserlat, Sara M, Supko, Jeffrey G, Haluska, Frank G, Louis, David N, Christiani, David C, Settleman, Jeff, Haber, Daniel A

“…Gefitinib, an inhibitor of the tyrosine kinase of the epidermal growth factor receptor (EGFR), is effective in less than 20 percent of patients with…”
Get full text

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling by McDermott, Ultan, Sharma, Sreenath V, Dowell, Lori, Greninger, Patricia, Montagut, Clara, Lamb, Jennifer, Archibald, Heidi, Raudales, Raul, Tam, Angela, Lee, Diana, Rothenberg, S. Michael, Supko, Jeffrey G, Sordella, Raffaella, Ulkus, Lindsey E, Iafrate, A. John, Maheswaran, Shyamala, Njauw, Ching Ni, Tsao, Hensin, Drew, Lisa, Hanke, Jeff H, Ma, Xiao-Jun, Erlander, Mark G, Gray, Nathanael S, Haber, Daniel A, Settleman, Jeffrey

“…Kinase inhibitors constitute an important new class of cancer drugs, whose selective efficacy is largely determined by underlying tumor cell genetics. We…”
Get full text

Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma by Pan, Edward, Supko, Jeffrey G., Kaley, Thomas J., Butowski, Nicholas A., Cloughesy, Timothy, Jung, Jinkyu, Desideri, Serena, Grossman, Stuart, Ye, Xiaobu, Park, Deric M.

“…Antiangiogenic therapies for malignant gliomas often result in transient response, and recurrent disease is characterized by adoption of invasive and hypoxic…”
Get full text

Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours by Konstantinopoulos, Panagiotis A., Cheng, Su-Chun, Supko, Jeffrey G., Polak, Madeline, Wahner-Hendrickson, Andrea E., Ivy, S. Percy, Bowes, Brittany, Sawyer, Hannah, Basada, Patrice, Hayes, Martin, Curtis, Jennifer, Horowitz, Neil, Wright, Alexi A., Campos, Susana M., Ivanova, Elena V., Paweletz, Cloud P., Palakurthi, Sangeetha, Liu, Joyce F., D’Andrea, Alan D., Gokhale, Prafulla C., Chowdhury, Dipanjan, Matulonis, Ursula A., Shapiro, Geoffrey I.

“…Purpose PARP inhibitor resistance may be overcome by combinatorial strategies with agents that disrupt homologous recombination repair (HRR). Multiple HRR…”
Get full text